Untypical Amlodipine-Induced Gingival Hyperplasia
Amlodipine is a third generation dihydropyridine calcium channel blocker that is frequently used in therapy of hypertension. Among many side effects, amlodipine has been found associated with gingival overgrowth (GO) which usually occurs within the first three months of starting therapy at a dose of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Dentistry |
| Online Access: | http://dx.doi.org/10.1155/2015/756976 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556298949885952 |
|---|---|
| author | Verica Pavlic Nina Zubovic Sanja Ilic Tijana Adamovic |
| author_facet | Verica Pavlic Nina Zubovic Sanja Ilic Tijana Adamovic |
| author_sort | Verica Pavlic |
| collection | DOAJ |
| description | Amlodipine is a third generation dihydropyridine calcium channel blocker that is frequently used in therapy of hypertension. Among many side effects, amlodipine has been found associated with gingival overgrowth (GO) which usually occurs within the first three months of starting therapy at a dose of 10 mg/day. However, there are very few reports on amlodipine-induced gingival overgrowth (AIGO) at a lower dose (5 mg/day) and only after short term administration. A 64-year-old male patient with hypertension, who received amlodipine (5 mg/day) for four years, sought medical attention at the Department of Periodontology and Oral Medicine, Institute of Dentistry, Banja Luka, Bosnia and Herzegovina. The patient complained of masticatory problems due to extensive maxillary GO along with pain, bleeding, and foul odor. The clinical and the histological evidences were consistent with AIGO. The first line treatment consisted of the amlodipine substitution (amlodipine was replaced with enalapril, 5 mg/day) and the scaling and root planning/SRP. At one-month follow-up, drug replacement and SRP resulted in some reduction of the inflammation and significant reduction of symptoms. Further, gingivectomy/gingivoplasty helped overcome the effect of these drugs. The possibility of AIGO should be considered for a lower dose, as well as a late presentation. |
| format | Article |
| id | doaj-art-ce37d53d91fd4ecd928353704f484aab |
| institution | Kabale University |
| issn | 2090-6447 2090-6455 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dentistry |
| spelling | doaj-art-ce37d53d91fd4ecd928353704f484aab2025-02-03T05:45:49ZengWileyCase Reports in Dentistry2090-64472090-64552015-01-01201510.1155/2015/756976756976Untypical Amlodipine-Induced Gingival HyperplasiaVerica Pavlic0Nina Zubovic1Sanja Ilic2Tijana Adamovic3Department of Periodontology and Oral Medicine, Institute of Dentistry, Zdrave Korde 4, 78000 Banja Luka, Bosnia and HerzegovinaDepartment of Periodontology and Oral Medicine, Institute of Dentistry, Zdrave Korde 4, 78000 Banja Luka, Bosnia and HerzegovinaDepartment of Endodontics, Institute of Dentistry, Zdrave Korde 4, 78000 Banja Luka, Bosnia and HerzegovinaDepartment of Periodontology and Oral Medicine, Medical Faculty University of Banja Luka, Bulevar Petra Bojovica 1, 78000 Banja Luka, Bosnia and HerzegovinaAmlodipine is a third generation dihydropyridine calcium channel blocker that is frequently used in therapy of hypertension. Among many side effects, amlodipine has been found associated with gingival overgrowth (GO) which usually occurs within the first three months of starting therapy at a dose of 10 mg/day. However, there are very few reports on amlodipine-induced gingival overgrowth (AIGO) at a lower dose (5 mg/day) and only after short term administration. A 64-year-old male patient with hypertension, who received amlodipine (5 mg/day) for four years, sought medical attention at the Department of Periodontology and Oral Medicine, Institute of Dentistry, Banja Luka, Bosnia and Herzegovina. The patient complained of masticatory problems due to extensive maxillary GO along with pain, bleeding, and foul odor. The clinical and the histological evidences were consistent with AIGO. The first line treatment consisted of the amlodipine substitution (amlodipine was replaced with enalapril, 5 mg/day) and the scaling and root planning/SRP. At one-month follow-up, drug replacement and SRP resulted in some reduction of the inflammation and significant reduction of symptoms. Further, gingivectomy/gingivoplasty helped overcome the effect of these drugs. The possibility of AIGO should be considered for a lower dose, as well as a late presentation.http://dx.doi.org/10.1155/2015/756976 |
| spellingShingle | Verica Pavlic Nina Zubovic Sanja Ilic Tijana Adamovic Untypical Amlodipine-Induced Gingival Hyperplasia Case Reports in Dentistry |
| title | Untypical Amlodipine-Induced Gingival Hyperplasia |
| title_full | Untypical Amlodipine-Induced Gingival Hyperplasia |
| title_fullStr | Untypical Amlodipine-Induced Gingival Hyperplasia |
| title_full_unstemmed | Untypical Amlodipine-Induced Gingival Hyperplasia |
| title_short | Untypical Amlodipine-Induced Gingival Hyperplasia |
| title_sort | untypical amlodipine induced gingival hyperplasia |
| url | http://dx.doi.org/10.1155/2015/756976 |
| work_keys_str_mv | AT vericapavlic untypicalamlodipineinducedgingivalhyperplasia AT ninazubovic untypicalamlodipineinducedgingivalhyperplasia AT sanjailic untypicalamlodipineinducedgingivalhyperplasia AT tijanaadamovic untypicalamlodipineinducedgingivalhyperplasia |